

Haematologica
HAEMATOL/2016/144576
Version 3

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: Data from 95 consecutive patients treated in a compassionate use program

Maria Winqvist, Anna Askid, Per-Ola Andersson, Karin Karlsson, Claes Karlsson, Birgitta Lauri, Jeanette Lundin, Mattias Mattsson, Stefan Norin, Anna Sandstedt, Lotta Hansson, and Anders Österborg

Disclosures: AÖ has received research grant support and honoraria for scientific lectures from Janssen. LH has received research grant support from Janssen. P-O A has received consulting honoraria from Janssen. None of the other authors declare any conflict of interest.

Contributions: MW, LH and AÖ designed the study, analysed the results, performed the statistical analyses and wrote the draft manuscript. All authors recruited and treated patients, filled out CRFs, interpreted the results, checked/modified and approved the manuscript.